title: Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.
abstract: Survival of metastatic gastroenteropancreatic well-differentiated endocrine carcinoma (GEP WDEC) is not well characterized. We evaluated the long-term outcome and prognostic factors for survival in 118 patients with distant metastases from GEP WDEC. Inclusion criteria were 1) pathological review by a single pathologist according to the present WHO criteria, 2) absence of previous therapy apart from surgery, 3) complete morphological evaluation within 3 months including somatostatin receptor scintigraphy, and 4) follow-up at Gustave-Roussy Institute until death or study's end. Clinical, biological marker, and pathological parameters were analyzed in univariate and multivariate statistical models. Survival after the first complete imaging work-up of the metastatic disease was determined using Kaplan-Meier method. Overall, survival for 5 years after the diagnosis of metastatic disease was 54%. In multivariate analysis, age (hazard ratio (HR): 1.05, 95% confidence interval (CI): 1.01-1.08, P = 0.01), the number of liver metastases (HR: 3.4, 95% CI: 1.4-8.3, P = 0.01), tumor slope (HR: 1.1, 95% CI: 1.0-1.1, P = 0.001), and initial surgery (HR: 0.3, 95% CI: 0.1-0.8, P = 0.01) were predictive of survival. Five-year survival was 100%, 91% (95% CI, 51-98%), 62% (95% CI, 37-83%), and 9% (95% CI, 6-32%) when patients had 0, 1, 2, 3 or more poor prognostic features respectively. This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials.
authors.affiliation: Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave-Roussy, Université Paris XI, 94805 Villejuif Cedex, France.
authors.forename: Cosimo
authors.initials: C
authors.lastname: Durante
authors.forename: Houda
authors.initials: H
authors.lastname: Boukheris
authors.forename: Clarisse
authors.initials: C
authors.lastname: Dromain
authors.forename: Pierre
authors.initials: P
authors.lastname: Duvillard
authors.forename: Sophie
authors.initials: S
authors.lastname: Leboulleux
authors.forename: Dominique
authors.initials: D
authors.lastname: Elias
authors.forename: Thierry
authors.initials: T
authors.lastname: de Baere
authors.forename: David
authors.initials: D
authors.lastname: Malka
authors.forename: Jean
authors.initials: J
authors.lastname: Lumbroso
authors.forename: Joël
authors.initials: J
authors.lastname: Guigay
authors.forename: Martin
authors.initials: M
authors.lastname: Schlumberger
authors.forename: Michel
authors.initials: M
authors.lastname: Ducreux
authors.forename: Eric
authors.initials: E
authors.lastname: Baudin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002454:Cell Differentiation; D002648:Child; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000401:mortality* / Q000556:secondary; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000401:mortality* / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000401:mortality* / Q000556:secondary; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D055815:Young Adult